CYCC - サイクラセル・ファ―マシュ―ティカルズ (Cyclacel Pharmaceuticals Inc.) サイクラセル・ファ―マシュ―ティカルズ



symbol CYCC
会社名 Cyclacel Pharmaceuticals Inc (サイクラセル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サイクラセル・ファーマシューティカルズ(Cyclacel Pharmaceuticals Inc.)は開発段階にあるバイオ製薬企業であり、ヒト癌とその他重篤な疾患を治療するメカニズムをターゲットとした医薬品の発見・開発・商業化に従事する。同社は米国とイギリスの2つの地域において開発事業を行う。同社はサパシタビン(sapacitabine)とセリシクリブ(seliciclib)が含まれる細胞周期に作用する複数の抗癌剤シリーズを生成している。同社は主に細胞周期の進行を減速したり、腫瘍のサーズを小さくしたりすることを目的とする、経口投与可能な抗癌剤の開発を中心とする。同社の臨床開発は高齢者急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)及び非小細胞肺癌(NSCLC)を含むサパシタビンを中心としている。同社は癌とその他重篤な疾患を治療するため、細胞周期制御における様々な段階をターゲットとする低分子薬の開発・商業化を行う。   サイクラセル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん及びその他重症疾患向け治療薬の開発・商品化に従事する。経口投与可能で、細胞分裂を抑止する小分子治験薬のパイプラインを推進する。主力候補薬には、急性骨髄性白血病治療薬の「Sapacitabine」がある。本社はニュ―ジャ―ジ―州。   Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies, including CLL and AML. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers and a concomitant regimen of sapacitabine and olaparib, a PARP inhibitor, in BRCA positive patients with breast cancer. CYC140, a PLK inhibitor, is in a Phase 1 first-in-human study in patients with advanced leukemias. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.
本社所在地 200 Connell Drive Suite 1500 Berkeley Heights NJ 07922 USA
代表者氏名 David Charles U'Prichard デビッドチャールズウプリアード
代表者役職名 Independent Chairman of the Board
電話番号 +1 908-517-7330
設立年月日 35065
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
EBITDA EBITDA(百万ドル) -8.90700
終値(lastsale) 1.39
時価総額(marketcap) 16676451.33
時価総額 時価総額(百万ドル) 16.31653
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -3.50747
当期純利益 当期純利益(百万ドル) -14.30400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cyclacel Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 14% to $3.3M. Lower net loss reflects Research and Development - other decrease of 24% to $1.9M (expense) Interest income increase from $30K to $153K (income) Stock-based Compensation in SGA decrease of 14% to $85K (expense). Dividend per share remained flat at $0.15.



   Cyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib  2022/04/12 12:55:23 Seeking Alpha
Shares of biopharmaceutical company Cyclacel Pharmaceuticals (CYCC) have added 13.2% in premarket trading on Tuesday after announcing publication of preclinical data confirming that…
   Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia  2022/04/12 11:00:00 GlobeNewswire
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia-
   Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript  2022/03/29 00:13:03 Seeking Alpha
   Cyclacel Pharmaceuticals GAAP EPS of -$1.34 (NASDAQ:CYCC)  2022/03/28 20:34:11 Seeking Alpha
Cyclacel Pharmaceuticals press release (CYCC): Q4 GAAP EPS of -$1.34.As of December 31, 2021, cash and cash equivalents totaled $36.6 million, compared to $33.4 million as of December…
   Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results  2022/03/28 20:05:00 GlobeNewswire
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –
   Geode Capital Management LLC Increases Stock Holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)  2021/11/29 09:06:44 Dakota Financial News
Geode Capital Management LLC increased its holdings in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 143.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,860 shares of the biotechnology companys stock after buying an additional 29,956 shares during the []
   Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Expected to Announce Earnings of -$0.66 Per Share  2021/11/24 00:40:41 Dakota Financial News
Wall Street brokerages expect that Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) will report earnings per share of ($0.66) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Cyclacel Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.63). Cyclacel Pharmaceuticals posted earnings per []
   Cyclacel Pharmaceuticals (NASDAQ:CYCC) Price Target Lowered to $17.00 at LADENBURG THALM/SH SH  2021/11/18 13:04:41 Dakota Financial News
Cyclacel Pharmaceuticals (NASDAQ:CYCC) had its price objective dropped by research analysts at LADENBURG THALM/SH SH from $18.00 to $17.00 in a research note issued to investors on Thursday, The Fly reports. The firm presently has a buy rating on the biotechnology companys stock. LADENBURG THALM/SH SHs price objective would suggest a potential upside of 264.03% []
   Boothbay Fund Management LLC Cuts Stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)  2021/11/15 11:40:43 Transcript Daily
Boothbay Fund Management LLC decreased its holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 66.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,545 shares of the biotechnology companys stock after selling 21,089 shares during the period. Boothbay Fund Management LLC owned approximately 0.11% of Cyclacel []
   Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript  2021/11/11 01:49:10 Seeking Alpha
   Cyclacel Pharmaceuticals Presenting at Three Conferences in September  2021/09/08 11:00:00 Investor Cyclacel
BERKELEY HEIGHTS, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three
   Community Youth Cultural Centre runs entrepreneurship training camp for the youth  2021/08/19 17:30:56 News Ghana
News Ghana, Latest Updates and Breaking News of Ghana, GNA, Community Youth Cultural Centre (CYCC) has organized a week-long programme in Accra to build the vocational and entrepreneurship capacity of some youth. The skills training programme held under the auspices of the Ministry of Tourism, Arts and Culture and the National Commission of Culture, []
   Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript  2021/08/12 00:30:42 Seeking Alpha
   Cyclacel Pharmaceuticals EPS misses by $0.07  2021/08/11 20:23:22 Seeking Alpha
   Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/11 20:05:00 Intrado Digital Media
- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET -

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイクラセル・ファ―マシュ―ティカルズ CYCC Cyclacel Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)